iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Akiram Therapeutics reported on October 13, 2026, that no dose-limiting toxicities (DLTs) had been observed among the first eight patients treated with its experimental radiopharmaceutical AKIR001. The sponsor also said treatment-related adverse events were limited to grades 1–2 and that four patients received repeat treatment. These are preliminary Phase I results from a small cohort—not proof that the treatment is definitively safe or effective.
What is AKIR001?
AKIR001, also written as [177Lu]Lu-AKIR001, is an investigational radiopharmaceutical: an antibody directed against the CD44v6 target is combined with lutetium-177, a therapeutic radioactive isotope. The approach is intended to deliver radiation to tumors expressing CD44v6. The October 13 announcement describes early clinical observations, not an approved or available treatment. Akiram Therapeutics’ announcement and the Karolinska University Hospital study record describe the agent and trial.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Print + eBook with... | $344.47 | Buy on Amazon |
| 2 |
|
Oxford Textbook of Palliative Medicine | $276.49 | Buy on Amazon |
| 3 |
|
Cancer Chemotherapy, Immunotherapy, and Biotherapy | $238.11 | Buy on Amazon |
| 4 |
|
Abeloff's Clinical Oncology | $264.99 | Buy on Amazon |
| 5 |
|
Textbook of Bladder Cancer | $669.67 | Buy on Amazon |
What did the first eight patients experience?
At the data cutoff reported by Akiram, eight patients had received treatment. The company reported zero observed DLTs, treatment-related adverse events limited to grades 1–2, and repeat treatment after the initial administration in four patients. The number eight is the treated cohort size, not a response rate or measure of clinical benefit.
A DLT is a treatment-related toxicity severe enough, under a study’s predefined rules and observation period, to limit dose escalation or further dosing. Reporting no DLTs means that none meeting that study definition had been observed in the evaluated patients; it does not mean there were no side effects. Akiram reported low-grade treatment-related events, but the announcement does not provide their individual types, frequency, severity details, or the study’s precise DLT criteria.
#1 Best Overall
What the imaging and biomarker findings suggest
Akiram said quantitative imaging showed sustained retention of the radiopharmaceutical in tumors while it cleared from blood and normal tissues. The company also reported that low CD44v6 expression measured by immunohistochemistry was consistently associated with low absorbed tumor doses.
Those observations may inform future study design and patient-selection research, but they do not establish a validated diagnostic test, a threshold for selecting patients, or a clinical benefit from selecting patients by CD44v6 expression. The announcement provides no controlled comparison or established efficacy result.
Rank #2
Who is the Phase I study for, and how is it designed?
The first-in-human Phase I study enrolls people with irresectable or metastatic CD44v6-positive solid tumors who have no remaining standard treatment options, according to the sponsor and the Karolinska University Hospital record for NCT06639191. The record describes a prospective, open-label study evaluating safety, tolerability, biodistribution, and anti-tumor effect. Participants receive an infusion followed by six weeks of safety follow-up, which may be extended to twelve weeks.
Akiram says the study is conducted at Karolinska University Hospital and identifies the hospital as sponsor. In a May 13, 2026 update, the company said its safety review had permitted progression to cohort 3 and that no DLTs had been seen in cohorts evaluated by that point. That earlier update provides dose-escalation context; it is not a substitute for the later eight-patient report.
Rank #3
What remains unknown
The October 13 announcement is a preliminary sponsor update ahead of the scheduled congress presentation. It does not provide detailed patient characteristics, administered activity levels, event-by-event safety data, full dosimetry results, or longer follow-up. Nor does it establish tumor response, survival benefit, or how AKIR001 compares with other treatments.
Accordingly, the findings should be read as an early safety and imaging snapshot. Eight treated patients and a short follow-up window cannot establish definitive safety, particularly for uncommon or delayed harms. The reported repeat dosing shows that four patients received another administration; it does not by itself show that repeat treatment is beneficial or suitable for other patients.
Rank #4
When is the next public update?
Akiram said preliminary results were selected as a Top Rated Oral Presentation at EANM 2026 in Vienna, scheduled for October 17–21. The company listed the AKIR001 presentation for October 18 as OP-172, with Joachim Nilsson as speaker. This was a scheduled presentation in the October 13 announcement; the announcement did not include the underlying abstract or a full clinical dataset.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
